Our approach to product development starts by identifying areas of unmet medical need where precision medicine could significantly improve disease staging and/or patient care decisions. We focus first on confirming the clinical challenges of these unmet needs and look for opportunities where current staging or standards of care do not sufficiently identify patient risk, or in areas where a patient’s biology can provide additional, actionable information to help guide treatment decisions.

Leveraging Advanced Technologies for Innovative Tests

Using our expertise in advanced technologies such as genomics, spatialomics and pharmacogenomics, data analytics and artificial intelligence, we dig deep into treatment pathways to develop clinically actionable tests that improve – and potentially transform – the management of diseases and patient outcomes.

Diseases are biologically complex and thus, it takes scientific diligence, stringent clinical protocols, machine learning expertise, proprietary algorithms, and the significant expertise of our world-class R&D team to develop highly accurate and actionable diagnostic and prognostic tests. Our Phoenix laboratory operates under CAP-accredited, CLIA-certified laboratory conditions, and we partner closely with academic researchers to complete multi-center clinical studies designed to validate the clinical utility and accuracy of our tests.

Using these techniques, we’ve successfully commercialized innovative tests that are helping patients with cancer and other diseases with high unmet clinical need. As we continue our active research and development programs, our goal is to truly transform disease management and continue to improve health through innovative tests that guide patient care.